ATE336509T1 - Verwendung von taci als antitumormittel - Google Patents

Verwendung von taci als antitumormittel

Info

Publication number: ATE336509T1
Authority: AT; Austria
Prior art keywords: taci; mammal; antitumor agent; reagent; administering
Prior art date: 2000-04-27

Application number

AT01927474T

Other languages

English (en)

Inventor

Christine Ambrose

Jeffrey Thompson

Pascal Schneider

Paul Rennert

Original Assignee

Biogen Idec Inc

Apoxis Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-27

Filing date

2001-04-27

Publication date

2006-09-15

2001-04-27 Application filed by Biogen Idec Inc, Apoxis Sa filed Critical Biogen Idec Inc

2006-09-15 Application granted granted Critical

2006-09-15 Publication of ATE336509T1 publication Critical patent/ATE336509T1/de

Links

239000002246 antineoplastic agent Substances 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 3
239000003153 chemical reaction reagent Substances 0.000 abstract 3
101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 abstract 2
102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 abstract 2
230000004663 cell proliferation Effects 0.000 abstract 1
230000004083 survival effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT01927474T 2000-04-27 2001-04-27 Verwendung von taci als antitumormittel ATE336509T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19994600P	2000-04-27	2000-04-27

Publications (1)

Publication Number	Publication Date
ATE336509T1 true ATE336509T1 (de)	2006-09-15

Family

ID=22739664

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01927474T ATE336509T1 (de)	2000-04-27	2001-04-27	Verwendung von taci als antitumormittel

Country Status (13)

Country	Link
EP (1)	EP1297013B1 (de)
JP (1)	JP2004513876A (de)
AT (1)	ATE336509T1 (de)
AU (2)	AU2001253920B2 (de)
CA (1)	CA2404945C (de)
CY (1)	CY1105788T1 (de)
DE (1)	DE60122337T2 (de)
DK (1)	DK1297013T3 (de)
ES (1)	ES2271004T3 (de)
NZ (1)	NZ521629A (de)
PT (1)	PT1297013E (de)
SI (1)	SI1297013T1 (de)
WO (1)	WO2001081417A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7217788B2 (en)	1996-03-14	2007-05-15	Human Genome Sciences, Inc.	Human tumor necrosis factor delta polypeptides
US6541224B2 (en)	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2281843T (pt)	2000-06-16	2017-01-02	Human Genome Sciences Inc	Anticorpos que se ligam imunoespecificamente a blys
AU2001288301A1 (en)	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
AU8506601A (en)	2000-08-18	2002-03-04	Dyax Corp	Binding polypeptides for b lymphocyte stimulator protein (blys)
AU2002215753A1 (en) *	2000-12-07	2002-06-18	The University Of British Columbia	Caml-binding peptides
EP1401870A4 (de)	2001-05-24	2006-04-19	Human Genome Sciences	Antikörper gegen tumor necrosis factor delta (april)
BRPI0209933B8 (pt)	2001-05-24	2021-05-25	Zymogenetics Inc	proteína de fusão, e, molécula de ácido nucleico
JP2007526220A (ja)	2003-06-05	2007-09-13	ジェネンテック・インコーポレーテッド	Ｂ細胞疾患の併用療法
US20070249530A1 (en)	2004-01-29	2007-10-25	Genentech, Inc.	Bcma Polypeptides and Uses Thereof
EP1922080A2 (de) *	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
WO2007019573A2 (en) *	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007142667A2 (en)	2005-10-13	2007-12-13	Human Genome Sciences, Inc.	Treatment of patients with autoantibody positive disease
ES2618543T3 (es)	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) *	2006-05-15	2012-01-17	Ares Trading Sa	métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
CN101323643B (zh) *	2007-06-15	2010-12-01	烟台荣昌生物工程有限公司	优化的TACI-Fc融合蛋白
HUE030134T2 (en)	2007-10-16	2017-04-28	Zymogenetics Inc	Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
GB201317929D0 (en) *	2013-10-10	2013-11-27	Ucl Business Plc	Chimeric antigen receptor
JP7385556B2 (ja) *	2017-09-01	2023-11-22	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用
JP7749319B2 (ja)	2017-10-10	2025-10-06	アルパインイミューンサイエンシズインコーポレイテッド	Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
EP4146684A2 (de)	2020-05-08	2023-03-15	Alpine Immune Sciences, Inc.	April- und baff-hemmende immunmodulatorische proteine mit und ohne t-zell-hemmendes protein und verfahren zur verwendung davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5969102A (en) *	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
SI1642972T1 (sl) *	1999-01-07	2010-05-31	Zymogenetics Inc	Terapevtske uporabe BR X topnih receptorjev
WO2000058362A1 (en) *	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon

2001
- 2001-04-27 DK DK01927474T patent/DK1297013T3/da active
- 2001-04-27 ES ES01927474T patent/ES2271004T3/es not_active Expired - Lifetime
- 2001-04-27 AT AT01927474T patent/ATE336509T1/de active
- 2001-04-27 JP JP2001578504A patent/JP2004513876A/ja not_active Withdrawn
- 2001-04-27 SI SI200130650T patent/SI1297013T1/sl unknown
- 2001-04-27 PT PT01927474T patent/PT1297013E/pt unknown
- 2001-04-27 AU AU2001253920A patent/AU2001253920B2/en not_active Ceased
- 2001-04-27 AU AU5392001A patent/AU5392001A/xx active Pending
- 2001-04-27 NZ NZ521629A patent/NZ521629A/en not_active IP Right Cessation
- 2001-04-27 CA CA2404945A patent/CA2404945C/en not_active Expired - Lifetime
- 2001-04-27 EP EP01927474A patent/EP1297013B1/de not_active Expired - Lifetime
- 2001-04-27 DE DE60122337T patent/DE60122337T2/de not_active Expired - Lifetime
- 2001-04-27 WO PCT/US2001/040626 patent/WO2001081417A2/en not_active Ceased
2006
- 2006-11-15 CY CY20061101667T patent/CY1105788T1/el unknown

Also Published As

Publication number	Publication date
ES2271004T3 (es)	2007-04-16
AU2001253920B2 (en)	2006-03-16
JP2004513876A (ja)	2004-05-13
DE60122337D1 (de)	2006-09-28
CY1105788T1 (el)	2011-02-02
DE60122337T2 (de)	2007-08-16
AU5392001A (en)	2001-11-07
SI1297013T1 (sl)	2007-06-30
CA2404945A1 (en)	2001-11-01
DK1297013T3 (da)	2006-12-27
NZ521629A (en)	2004-05-28
PT1297013E (pt)	2006-12-29
WO2001081417A3 (en)	2002-06-20
WO2001081417A2 (en)	2001-11-01
EP1297013B1 (de)	2006-08-16
EP1297013A2 (de)	2003-04-02
CA2404945C (en)	2010-02-09

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1297013

Country of ref document: EP

Publication	Publication Date	Title
ATE336509T1 (de)	2006-09-15	Verwendung von taci als antitumormittel
ATE441418T1 (de)	2009-09-15	Verwendung von treprostinil zur verbesserung der nierenfunktion
PT1140944E (pt)	2004-01-30	Derivados de epotilona e sua utilizacao como agentes antitumorais
NO20060600L (no)	2006-04-18	Spesifikke bindingsmidler for hepatocytt vekstfaktorer
TR200102800T2 (tr)	2002-01-21	Yeni bileşikler.
PT892780E (pt)	2003-02-28	Analogos de m-amidino fenilo como inibidores do factor xa
HN1998000143A (es)	1999-04-09	Tetrahidronaftalenos substituidos y compuestos analogos.
ATE430589T1 (de)	2009-05-15	Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
ATE246197T1 (de)	2003-08-15	Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
EA200200105A1 (ru)	2002-06-27	СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
ATE363280T1 (de)	2007-06-15	Verwendung von pioglitazone zur verbesserung der ketose und der azidose
CR6393A (es)	2004-03-24	Moduladores de ccr5
EP0986382A4 (de)	2001-04-11	Raf kinase hemmer
EA200201119A1 (ru)	2003-06-26	Лиганды меланокортиновых рецепторов
IL143569A0 (en)	2002-04-21	A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
PL2274373T3 (pl)	2012-09-28	Mieszaniny zmiatające tlen
BR0108046A (pt)	2003-01-28	Compostos azol condensados e seu uso como agentes hipoglicêmicos
EA200800889A1 (ru)	2008-12-30	Гексагидроциклооктилпиразольные каннабиноидные модуляторы
DE50114181D1 (de)	2008-09-11	Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
ID28892A (id)	2001-07-12	Sintesa heteropoliasida
ES2097798T3 (es)	1997-04-16	Reactivo oxidable productor de color.
UA94231C2 (ru)	2011-04-26	Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
TR200000624T2 (tr)	2000-11-21	Bir enzimin etkinliğinin arttırılması ile ilgili bir yöntem.
DE60014048D1 (de)	2004-10-28	1,5-anhydro-d-fruktose substituiert mit einer hydrophoben gruppe zur verwendung als antioxidant und/oder emulgator
ATE238791T1 (de)	2003-05-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum